KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to 0.69.

  • Aurinia Pharmaceuticals' Equity Ratio fell 182.8% to 0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69, marking a year-over-year decrease of 182.8%. This contributed to the annual value of 0.69 for FY2024, which is 59.44% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Equity Ratio is 0.69, which was down 182.8% from 0.67 recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Equity Ratio registered a high of 0.89 during Q1 2021, and its lowest value of 0.67 during Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Equity Ratio value was 0.71 (recorded in 2023), while the average stood at 0.78.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 471.56% in 2022, then plummeted by 1990.97% in 2023.
  • Aurinia Pharmaceuticals' Equity Ratio (Quarter) stood at 0.88 in 2021, then dropped by 2.34% to 0.86 in 2022, then fell by 19.91% to 0.69 in 2023, then dropped by 0.59% to 0.69 in 2024, then increased by 1.14% to 0.69 in 2025.
  • Its Equity Ratio was 0.69 in Q3 2025, compared to 0.67 in Q2 2025 and 0.69 in Q1 2025.